BRÈVE

sur VETOQUINOL (EPA:VETO)

Vetoquinol Reports 9-Month Sales Decline, Despite Essential Product Growth

Graphique de l'évolution du cours de l'action VETOQUINOL (EPA:VETO).

Vetoquinol reported a 3.5% decline in sales at the end of September 2025, amounting to €384.2 million. At constant exchange rates, sales fell by 1.3%. The company experienced a €8.9 million negative currency impact across the Americas and Asia-Pacific, alongside a €7.7 million impact from simplifying complementary product ranges, particularly in Europe.

Despite the overall decline, sales of Essential products rose to €244.2 million, making up 64% of total sales, marking a 2.7% increase at constant exchange rates. This internal growth reflects ongoing adjustments from the transfer of certain product manufacturing to Vetoquinol's facilities.

Regional performance varied: European sales decreased, partly due to product line simplification, while the U.S. showed a 7.5% organic increase in Q3 2025, boosting its 9-month growth to 1.2%. Companion animal products generated €276 million, representing 72% of sales.

R. E.

Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de VETOQUINOL